Mergers & Acquisitions
Jul. 29, 2015
Sullivan, Latham advise in Teva's $40.5 billion buyout offer of Activis
Consolidation volume in the pharmaceutical market broke financial records Monday after Teva Pharmaceuticals Industries Ltd. announced a $40.5 billion buyout offer of Allergan PLC's generic drugmaking branch Actavis PLC.




Daily Journal Staff Writer
Annual consolidation volume in the pharmaceutical market broke financial records Monday
after Teva Pharmaceuticals Industries Ltd. announced a $40.5 billion buyout offer
of Allergan PLC's generic drugmaking branch Actavis PLC, an effort aided by attorneys
from Sullivan & Cromwell LLP.
Latham & Watkins LL...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In